Humanization of an anti-human IL-6 mouse monoclonal antibody glycosylated in its heavy chain variable region

Human Antibodies

Volumn 7, Issue 4, 1996, Pages 175-183

  Sato, Koh ^a   Ohtomo, Toshihiko ^a   Hirata, Yuichi ^a   Saito, Hiroyuki ^a   Matsuura, Tetsu ^a   Akimoto, Toshio ^a   Akamatsu, Ken Ichi ^a   Koishihara, Yasuo ^a   Ohsugi, Yoshiyuki ^a   Tsuchiya, Masayuki ^a  

^a CHUGAI PHARMACEUTICAL CO LTD   (Japan)

Author keywords

Glycosylation; Humanization; IL 6; Monoclonal antibody

Indexed keywords

CARBOHYDRATE; CHIMERIC ANTIBODY; IMMUNOGLOBULIN F(AB) FRAGMENT; IMMUNOGLOBULIN HEAVY CHAIN; IMMUNOGLOBULIN LIGHT CHAIN; INTERLEUKIN 6; INTERLEUKIN 6 ANTIBODY; INTERLEUKIN 6 RECEPTOR; MONOCLONAL ANTIBODY;

AMINO ACID SEQUENCE; AMINO ACID SUBSTITUTION; ANIMAL CELL; ANIMAL EXPERIMENT; ANTIBODY PRODUCTION; ANTIGEN BINDING; ARTICLE; BINDING SITE; BIOSENSOR; CONTROLLED STUDY; DISSOCIATION CONSTANT; GLYCOSYLATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN CONFORMATION; RECEPTOR BINDING; SCATCHARD PLOT;

AMINO ACID SEQUENCE; ANIMALS; ANTIBODIES, MONOCLONAL; ANTIGEN-ANTIBODY REACTIONS; CELLS, CULTURED; ENZYME-LINKED IMMUNOSORBENT ASSAY; GLYCOSYLATION; HUMANS; IMMUNOGLOBULIN FAB FRAGMENTS; IMMUNOGLOBULIN HEAVY CHAINS; IMMUNOGLOBULIN VARIABLE REGION; INTERLEUKIN-6; MICE; MODELS, CHEMICAL; MOLECULAR SEQUENCE DATA;

EID: 0030428215     PISSN: 10932607     EISSN: 1875869X     Source Type: Journal    
DOI: 10.3233/HAB-1996-7405     Document Type: Article

References (37)

1. Kishimoto T. The biology of interleukin-6. Blood 1989; 74: 1
2. Hirano T, Akira T, Taga T, Kishimoto, T. Biological and clinical aspects of interleukin-6. Imm Today 1990; 11: 443
3. Taga T, Hibi M, Hirata Y, Yamasaki K, Yasukawa K, Matsuda T, Hirano T, Kishimoto T. Interleukin-6 triggers the association of its receptor with a possible signal transducer, gpl30. Cell 1989; 58: 573
4. Klein B, Zhang XG, Jourdan M, Boiron JM, Portier M, Lu ZY, Wijdenes J, Brochier J, Bataille R. Interleukin-6 is the central tumor growth factor in vitro and in vivo in multiple myeloma. Eur Cytokine Net 1990; 1: 193
5. Roodman, GD, Kurihara N, Ohsaki Y, Kukita A, Hosking D, Demulder A, Smith JF, Singer FR. Interleukin 6. A potential autocrine/paracrine factor in Paget’s disease of bone. J Clin Invest 1992; 89: 46
6. Klein B, Lu ZY, Bataille R. Clinical applications of IL6 inhibitors. Res Immunol 1992; 143: 774
7. Klein B, Wijdenes J, Zhang XG, Jourdan M, Boiron JM, Brochier J, Liautard J, Merln M, Clement C, Morel-Fournier B, Lu ZY, Mannonl P, Sany J, Bataille R. Murine anti-interleukin-6 monoclonal antibody therapy for a patient with plasma cell leukemia. Blood 1991; 78: 1198
8. Wendling D, Racadot E, Wijdenes J. Treatment of severe rheumatoid arthritis by anti-interleukin 6 monoclonal antibody. J Rheumatol 1993; 20: 259
9. Suzuki H, Yasukawa K, Saito T, Goitsuka R, Hasegawa A, Ohsugi Y, Taga T, Kishimoto T. Anti-human interleukin 6 receptor antibody inhibits human myeloma growth in vivo. Eur J Immunol 1992; 22: 1989
10. Riechmann L, Clark M, Waldman H, Winter G. Reshaping human antibodies for therapy. Nature 1988; 322: 323
11. Sato K, Tsuchiya M, Saldanha J, Koishihara Y, Ohsugi Y, Kishimoto T, Bendig MM. Reshaping a human antibody to inhibit the interleukin 6-dependent tumor cell growth. Cancer Res 1993; 53: 851
12. Sato K, Tsuchiya M, Saldanha J, Koishihara Y, Ohsugi Y, Kishimoto T, Bendig MM. Humanization of a mouse anti-human interleukin-6 receptor antibody comparing two methods for selecting human framework regions. Mol Immun 1994; 31: 371
13. Brakenhoff JPJ, de Hon FD, Fontaine V, ten Boekel E, Schooltink H, Rose-John S, Heinrich PC, Content J, Aarden LA. Development of a Human Interleukin-6 Receptor Antagonist. J Biol Chem 1994; 269: 86
14. Kabat EA, Wu TT, Reid-Miller M, Perry HM, Gottesman KS. Sequences of Proteins of Immunological Interest (US Dept Health and Human Services, US Government Printing Offices) 1991
15. Spiegelberg HL, Abel CA, Fishkin BG, Grey HM. Localization of the carbohydrate within the variable region of light and heavy chains of human gamma g myeloma proteins. Biochemistry 1970; 9: 4217
16. Wright A, Tao M, Kabat EA, Morrison SL. Antibody variable region glycosylation: Position effects on antigen binding and carbohydrate structure. EMBO J 1991; 10: 2717
17. Wright A, Morrison SL. Antibody variable region glycosylation: Biochemical and clinical effects. Springer Semin Immunopathol 1993; 15: 259
18. Matsuda T, Hirano T, Kishimoto T. Establishment of an interleukin 6 (IL6)/B cell stimulatory factor 2-dependent cell line and preparation of anti-IL6 monoclonal antibodies. Eur J Immunol 1988; 18: 951
19. Jones ST, Bendig MM. Rapid PCR-cloning of full-length mouse immunoglobulin variable regions. Bio Technol 1991; 9: 88
20. Maeda H, Matsushita S, Eda Y, Kimachi K, Tokiyoshi S, Bendig MM. Construction of reshaped human antibodies with HIV-neutralizing activity. Hum Antibod Hybridomas 1991; 2: 124
21. Hirata Y, Taga T, Hibi M, Nakano N, Hirano T, Kishimoto T. Characterization of IL-6 receptor expression by monoclonal and polyclonal antibody. J Immunol 1989; 143: 2900
22. Yasukawa K, Saito T, Fukunaga T, Sekimori Y, Koishihara Y, Fukui H, Ohsugi Y, Matsuda Y, Yawata H, Hirano T, Taga T, Kishimoto T. Purification and characterization of soluble human IL-6 receptor expressed in CHO cells. J Biochem 1990; 108: 673
23. Okuno Y, Takahashi T, Suzuki A, Ichiba S, Nakamura K, Hitomi K, Sasaki R, Imura H. Expression of the erythropoietin receptor on a human myeloma cell line. Biochem Biophys Res Commun 1990; 170: 1128
24. Shimizu S, Yoshioka R, Hirose Y, Sugai S, Tachibana J, Konda S. Establishment of two interlukin 6 (B cell stimulatory factor/ interferon /?2)-dependent human bonemarrow-derived myeloma cell lines. Exp Med 1989; 169: 339
25. Shimizu S, Takiguchi T, Sugai S, Matsuoka M, Konda S. An established CD4+ T lymphoma cell line derived from a patient with so-called lennert’s lymphoma: Possible roles of cytokines in histopathogenesis. Blood 1988; 71: 196
26. Chothia C, Lesk AM. Canonical structure for the hypervariable regions of immunoglobulins. J Mol Biol 1987; 196: 901
27. Chothia C, Lesk AM, Tramontano A, Levitt M, Smith-Gill SJ, Air G, Sheriffs, Padlan EA, Davis D, Tulip WR, Colman PM, Spinelli S, Alzari PM, Poljak RJ. Conformations of immunoglobulin hypervariable regions. Nature 1989; 34: 877
28. Palm W, Hilschmann N. Die primarstrukutur einer kristallinen monoklonalen immunoglobulin L kette vom k-typ, subgruppe I (Bence-Jones-Portein Rei), isolierung und Charakterisierung der tryptischen peptide; die vollständige aminos auresequenz des proteins. Physiol Chem 1975; 356: 167
29. Press EM, Hogg NM. The amino acid sequences of the Fd frag¬ments of two human gamma-1 heavy chains. Biochem J1970; 117: 641
30. Wright A, Morrison SL. Springer Semin Immunopathol 1993; 15: 259
31. Co MS, Scheinberg DA, Avdalovic NM, McGraw K, Vasquez M, Carton P, Queen C. Genetically engineered deglycosylation of the variable domain increases the affinity of an anti-CD33 monoclonal antibody. Mol Immunol 1993; 30: 1361
32. Kato M, Mochizuki K, Hashizume S, Tachibana H, Shirahata S, Murakami H. Activity enhancement of a lung cancer-associated human monoclonal antibody HB4C5 by N-deglycosylation. Hum Antibod Hybridomas 1993; 4: 9
33. Tachibana H, Seki K, Murakami H. Identification of hybrid-type carbohydrate chains on the light chain of human monoclonal antibody specific to lung adenocarcinoma. Biochem Biophys Acta 1993; 1182: 257
34. Co MS, Avdalovic NM, Carton PC, Avdalovic MV, Scheinberger DA, Queen C. Chimeric and humanized antibodies with specificity for the CD33 antigen. J Immunol 1992; 148: 1149
35. Legouffe E, Liautard J, Gaillard JP, Rossi JF, Wijdenes J, Bataille R, Klein B, Brochier J. Human anti-mouse antibody response to the injection of murine monoclonal antibodies against IL-6. Clin Exp Immunol 1994; 98: 323
36. Bataille R, Barlogie B, Lu ZY, Rossi JF, Lavabrebetrand T, Beck T, Wijdenes J, Brochier J, Klein B. Biologic effects of anti-interleukin-6-murine monoclonal antibody in advanced multiple myeloma. Blood 1995; 86: 685
37. Tsunenari T, Akamatsu K, Kaiho S, Sato K, Tsuchiya M, Koishihara Y, Kishimoto T, Ohsugi Y. Therapeutic potential of humanized anti-interleukin-6 receptor antibody: Antitumor activity in xenograft model of multiple myeloma. Anticancer Res 1996; 16: 2537